UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 645

Sortiert nach

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

Journal of thrombosis and haemostasis, 2006-04, Vol.4 (4), p.766-773

2006

Volltextzugriff (PDF)

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-07, Vol.19 (4), p.564-570

2013

Volltextzugriff (PDF)

New findings on inhibitor development: from registries to clinical studies

Haemophilia : the official journal of the World Federation of Hemophilia, 2017-01, Vol.23 (S1), p.4-13

2017

Volltextzugriff (PDF)

Costs and management of patients with hemophilia A in France: the Hemraude study

The European journal of health economics, 2022-02, Vol.23 (1), p.23-32

2022

Volltextzugriff (PDF)

Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-12, Vol.13 (s5), p.47-51

GOUDEMAND, J.

2007

Volltextzugriff (PDF)

Coagulation standards in healthy newborns and infants

Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2021-02, Vol.28 (2), p.156-158

2021

Volltextzugriff (PDF)

FXI concentrate use and risk of thrombosis

Haemophilia : the official journal of the World Federation of Hemophilia, 2014-07, Vol.20 (4), p.e349-e351

2014

Volltextzugriff (PDF)

Response to Wiewel-Verschueren S et al.: gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review

Haemophilia : the official journal of the World Federation of Hemophilia, 2016-09, Vol.22 (5), p.e435-e436

2016

Volltextzugriff (PDF)

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Haemophilia : the official journal of the World Federation of Hemophilia, 2015-07, Vol.21 (4), p.481-489

2015

Volltextzugriff (PDF)

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

Journal of thrombosis and haemostasis, 2008-05, Vol.6 (5), p.762-771

2008

Volltextzugriff (PDF)

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Haemophilia : the official journal of the World Federation of Hemophilia, 2010-11, Vol.16 (6), p.866-877

2010

Volltextzugriff (PDF)

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

Journal of thrombosis and haemostasis, 2007-06, Vol.5 (6), p.1115-1124

2007

Volltextzugriff (PDF)

Fifth Åland Island conference on von Willebrand disease

Haemophilia : the official journal of the World Federation of Hemophilia, 2018-05, Vol.24 (S4), p.5-19

2018

Volltextzugriff (PDF)

Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure

Haemophilia : the official journal of the World Federation of Hemophilia, 2013-09, Vol.19 (5), p.e296-e298

2013

Volltextzugriff (PDF)

Treatment of patients with inhibitors: cost issues

Haemophilia : the official journal of the World Federation of Hemophilia, 1999-11, Vol.5 (6), p.397-401

Goudemand

1999

Volltextzugriff (PDF)

Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial

Thrombosis and haemostasis, 2010-02, Vol.103 (2), p.351

2010

Volltextzugriff (PDF)

A new ELISA assay for diagnosis of acquired von Willebrand Syndrome

Haemophilia : the official journal of the World Federation of Hemophilia, 2003-05, Vol.9 (3), p.303-308

2003

Volltextzugriff (PDF)

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

Journal of thrombosis and haemostasis, 2006-04, Vol.4 (4), p.774-782

2006

Volltextzugriff (PDF)

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis

Haemophilia : the official journal of the World Federation of Hemophilia, 2011-11, Vol.17 (6), p.944-951

2011

Volltextzugriff (PDF)

Inhibitor incidence with recombinant vs. plasma‐derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies

Journal of thrombosis and haemostasis, 2008-02, Vol.6 (2), p.390-392

2008

Volltextzugriff (PDF)

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

Journal of thrombosis and haemostasis, 2005-10, Vol.3 (10), p.2219-2227

2005

Volltextzugriff (PDF)

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

Journal of thrombosis and haemostasis, 2009-08, Vol.7 (8), p.1304-1312

2009

Volltextzugriff (PDF)

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels

Journal of thrombosis and haemostasis, 2010-09, Vol.8 (9), p.1986-1993

2010

Volltextzugriff (PDF)

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Haemophilia : the official journal of the World Federation of Hemophilia, 2007-05, Vol.13 (3), p.256-263

2007

Volltextzugriff (PDF)

Double-blind, Placebo-controlled Trial of Antithrombin III Concentrates in Septic Shock With Disseminated Intravascular Coagulation

Chest, 1993-09, Vol.104 (3), p.882-888

1993

Volltextzugriff (PDF)

1 – 25 von 645

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(335)
Mit Volltextzugriff
(315)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(408)
Male
(169)
Female
(165)
Adult
(164)
Science & Technology
(160)
Life Sciences & Biomedicine
(155)
Middle Aged
(122)
Hematology
(105)
Adolescent
(78)
Biological And Medical Sciences
(74)
Child
(72)
Medical Sciences
(68)
Aged
(67)
Sciences Biologiques Et Medicales
(53)
Old Medline
(52)
Sciences Medicales
(51)
Child, Preschool
(43)
Hematologic And Hematopoietic Diseases
(36)
Platelet Diseases And Coagulopathies
(32)
Animals
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM‐1 VWD)

Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hémophilie Acquise) registry

New findings on inhibitor development: from registries to clinical studies

Costs and management of patients with hemophilia A in France: the Hemraude study

Inhibitor development in haemophilia A: the role of von Willebrand factor/factor VIII concentrates

Coagulation standards in healthy newborns and infants

FXI concentrate use and risk of thrombosis

Response to Wiewel-Verschueren S et al.: gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review

Factor XI replacement for inherited factor XI deficiency in routine clinical practice: results of the HEMOLEVEN prospective 3-year postmarketing study

Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM‐1VWD)

Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice

Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients

Fifth Åland Island conference on von Willebrand disease

Colonoscopy in patients with haemophilia: the duration of clotting factor coverage must be adjusted to suit the procedure

Treatment of patients with inhibitors: cost issues

Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial

A new ELISA assay for diagnosis of acquired von Willebrand Syndrome

Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD

Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis

Inhibitor incidence with recombinant vs. plasma‐derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies

Pharmacokinetic studies on Wilfactin®, a von Willebrand factor concentrate with a low factor VIII content treated with three virus‐inactivation/removal methods

Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM‐1VWD study

von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels

A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors

Double-blind, Placebo-controlled Trial of Antithrombin III Concentrates in Septic Shock With Disseminated Intravascular Coagulation

Suchergebnisse filtern